← The Wire·Earnings·

Olema shares slide 15.1% after AstraZeneca SERENA-4 results

Olema Pharmaceuticals shares fell 15.1% after AstraZeneca reported SERENA-4 trial results, highlighting a potential competitive read-through for Olema’s breast-cancer program. The move puts greater weight on Olema’s own clinical differentiation and upcoming pipeline updates.

AstraZeneca’s Discovery Centre, Cambridge — file photoFile photo · AstraZeneca’s Discovery Centre, Cambridge · Nov 2021 · John Sutton · CC BY-SA 2.0 · Source & license

The story

Olema Pharmaceuticals shares fell 15.1% following AstraZeneca's SERENA-4 trial results. The trial's efficacy figures, specific endpoint, and how the results change the outlook for Olema's program remain unclear, making the competitive read-through difficult to quantify.

The market reaction indicates that investors treated the AstraZeneca data as relevant to Olema's development strategy, though whether the concern is about efficacy, treatment sequencing, safety, or commercial positioning is uncertain. AstraZeneca is the directly named large-cap company in the wider company data, with FY2025 revenue of $58.7B, up 8.6% year over year, and diluted EPS of $6.54. Those figures describe AstraZeneca's older full-year performance rather than the SERENA-4 readout and do not establish the trial's commercial impact.

The immediate open questions are the detailed SERENA-4 results, Olema's response, and the next clinical update for Olema's pipeline.

Our read · Mon, Sep 14

The SERENA-4 read-through shifts near-term clinical risk to the downside for OLMA, while AZN’s broader financial profile is not enough to quantify a direct trial impact.

Why. The immediate consequence is a higher perceived competitive hurdle for OLMA. AZN’s FY2025 revenue of $58.7B and 17.4% net margin provide scale context, not evidence of the SERENA-4 read-through’s effect on Olema.

Both cases

The case it holdsOlema could recover if the detailed SERENA-4 results do not materially alter the competitive landscape or if its own pipeline update demonstrates differentiation.
The case it breaksThe only concrete negative evidence is the 15.1% share-price fall after AstraZeneca’s trial results; without the underlying data, the case cannot yet be strengthened beyond that market reaction.

What could change this view: The downside read fails if the full SERENA-4 data are clinically limited or Olema’s next update shows differentiated efficacy or positioning.

Olma stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Since this story · the companies named here, equal weight · −11.7%

Sep 14 · first close after publicationNov 19

Price context does not establish that the story caused the move.

Keep reading

Latest on the Wire

German producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsAMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions rise
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Yahoo Finance as Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →